CENTOGENE NV (CNTG)

NL0014040206 - Common Stock

0.325  -0.02 (-6.23%)

After market: 0.351 +0.03 (+8%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

CENTOGENE NV

NASDAQ:CNTG (8/7/2024, 8:06:53 PM)

After market: 0.351 +0.03 (+8%)

0.325

-0.02 (-6.23%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Providers & Services
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-68.45%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap8.97M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

CNTG Daily chart

Company Profile

Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. The company is headquartered in Rostock, Mecklenburg-Vorpommern and currently employs 493 full-time employees. The company went IPO on 2019-11-07. The firm focuses on rare diseases, transforming clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The firm's platform includes epidemiological, phenotypic, and genetic data reflecting a global population, as well as a biobank of blood samples from these patients. The firm's pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The firm's Clinical Diagnostics segment provides targeted genetic sequencing and diagnostic services to patients through its distribution partners and customers, which are typically physicians, laboratories or hospitals.

Company Info

CENTOGENE NV

Am Strande 7

Rostock MECKLENBURG-VORPOMMERN 18055

P: 4938180113400

CEO: Andrin Oswald

Employees: 493

Website: https://www.centogene.com/

CNTG News

News Image15 days ago - Centogene NVCENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners
News Image15 days ago - Centogene NVCENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) (“CENTOGENE” or the “Company”), the...

News Image2 months ago - Centogene NVCENTOGENE Data on Novel Genetic Risk Factor for Parkinson’s Disease in The Lancet Neurology
News Image2 months ago - Centogene NVCENTOGENE Data on Novel Genetic Risk Factor for Parkinson’s Disease in The Lancet Neurology

Rostock International Parkinson's Disease (ROPAD) Study demonstrates a significant link between the RAB32 gene variant and Parkinson's disease, further...

News Image4 months ago - Centogene NVCENTOGENE Receives Delisting Notice From Nasdaq
News Image4 months ago - Centogene NVCENTOGENE Receives Delisting Notice From Nasdaq

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Centogene N.V., the essential life science partner for data-driven...

CNTG Twits

Here you can normally see the latest stock twits on CNTG, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example